Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction

被引:168
作者
Boekholdt, SM
Bijsterveld, NR
Moons, AHM
Levi, M
Büller, HR
Peters, RJG
机构
[1] Acad Med Ctr, Dept Cardiol, NL-1100 DD Amsterdam, Netherlands
[2] Acad Med Ctr, Dept Internal Med, NL-1100 DD Amsterdam, Netherlands
[3] Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands
关键词
myocardial infarction; genetics; coagulation;
D O I
10.1161/hc5001.100793
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - It is pathophysiologically conceivable that genetic variations in coagulation and fibrinolytic proteins are associated with the risk of myocardial infarction. Methods and Results - We performed a literature search to identify published case-control studies correlating the factor V Leiden or prothrombin G20210A mutations or fibrinogen G-455A or plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphisms with the risk of myocardial infarction. Studies were included only if they used solid diagnostic criteria and complied with published methodological criteria. A common OR with corresponding 95% CI was calculated for the risk of myocardial infarction in a fixed-effect model according to Mantel-Haenszel. The factor V Leiden and prothrombin G20201A mutations did not significantly correlate with myocardial infarction (OR 1.26, 95% CI 0.94 to 1.67, P = 0.12 and OR 0.89, 95% CI 0.59 to 1.35, P = 0.6, respectively). Inclusion of the studies that investigated young patients (< 55 years) made the association significant for factor V Leiden (OR 1.29, 95% CI 1.03 to 1.61, P = 0.02). Homozygosity for the fibrinogen -455A allele was significantly associated with a decreased risk of myocardial infarction (OR 0.66, 95% CI 0.44 to 0.99, P = 0.04), whereas the PAI-14G4G genotype was significantly associated with increased risk (OR 1.20, 95% CI 1.04 to 1.39, P = 0.04). Conclusions-Associations between these genetic variations and myocardial infarction were weak or absent. In the absence of clinical implications, our results indicate that screening of patients with myocardial infarction for these genetic variations is not warranted.
引用
收藏
页码:3063 / 3068
页数:6
相关论文
共 52 条
  • [1] Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction
    Anderson, JL
    Muhlestein, JB
    Habashi, J
    Carlquist, JF
    Bair, TL
    Elmer, SP
    Davis, BP
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (06) : 1778 - 1783
  • [2] Ardissino D, 1999, BLOOD, V94, P46
  • [3] Ardissino D, 1996, THROMB HAEMOSTASIS, V75, P701
  • [4] Prevalence of the prothrombin gene variant 20210 G→A among patients with myocardial infarction
    Arruda, VR
    Siquiera, LH
    Chiaparini, LC
    Coelho, OR
    Mansur, AP
    Ramires, A
    Annichino-Bizzacchi, JM
    [J]. CARDIOVASCULAR RESEARCH, 1998, 37 (01) : 42 - 45
  • [5] Arruda VR, 1997, THROMB HAEMOSTASIS, V78, P1430
  • [6] Clinical epidemiological quality in molecular genetic research - The need for methodological standards
    Bogardus, ST
    Concato, J
    Feinstein, AR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (20): : 1919 - 1926
  • [7] Genetic polymorphisms and coronary artery disease in the south of France
    Canavy, I
    Henry, M
    Morange, PE
    Tiret, L
    Poirier, O
    Ebagosti, A
    Bory, M
    Juhan-Vague, I
    [J]. THROMBOSIS AND HAEMOSTASIS, 2000, 83 (02) : 212 - 216
  • [8] Croft SA, 1999, THROMB HAEMOSTASIS, V81, P861
  • [9] Cushman M, 1998, THROMB HAEMOSTASIS, V79, P912
  • [10] DAWSON SJ, 1993, J BIOL CHEM, V268, P10739